Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01058083 · ClinicalTrials.gov registry record · Phase 2
Safety Study of BMS-770767 in Subjects With Hypercholesterolemia
A Phase 2 study of Dyslipidemia, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 14
- Study locations
NCT01058083: Completed Phase 2 study of Dyslipidemia, sponsored by Bristol-Myers Squibb.
NCT01058083 is a Phase 2 study of Dyslipidemia that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 81 participants, below the 361-participant average among 40 other Dyslipidemia trials with a reported enrollment target (78% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01058083, a Phase 2 study of Dyslipidemia, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BMS-770767
Study Locations (14)
New South Wales
- Local Institution - Blacktown
- Local Institution - Hornsby
Queensland
- Local Institution - Caboolture
- Local Institution - South Brisbane
Ontario
- Local Institution - Brampton
- Local Institution - Toronto
Quebec
- Local Institution - Mirabel
- Local Institution - Montreal
Arkansas
- Harrell, Robert - Little Rock
Texas
- Cetero Research - San Antonio - San Antonio
South Australia
- Local Institution - Daw Park
Western Australia
- Local Institution - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
What the finished NCT01058083 record still lists
NCT01058083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 361-participant average among 40 other Dyslipidemia trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Dyslipidemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01058083 lists 14 locations in 10 states (New South Wales, Queensland, Ontario).
Frequently Asked Questions
What is clinical trial NCT01058083 about?
NCT01058083 is a clinical study titled "Safety Study of BMS-770767 in Subjects With Hypercholesterolemia". The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)
What is the current status of trial NCT01058083?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2010-05. Estimated completion is 2011-03.
What conditions does trial NCT01058083 study?
This clinical trial studies the following conditions: Dyslipidemia.
What interventions are being tested in trial NCT01058083?
The interventions under investigation include: Placebo (DRUG), BMS-770767 (DRUG).
Who is sponsoring clinical trial NCT01058083?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01058083 being conducted?
This trial has 14 study locations across Arkansas, Texas, New South Wales, Queensland, South Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01058083's enrollment target sits among peer trials
81 24th of 40 higher than 16 of 40 other Dyslipidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preliminary Study of Safety and Efficacy of Policosanol
COMPLETED · Phase 2
-
Fenofibrate Treatment in SCI
COMPLETED · Phase 2
-
Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women
COMPLETED · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
COMPLETED · Phase 2
-
Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia
COMPLETED · Phase 2
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia